New drug QRX-3 aims to speed kidney recovery in hospital patients

NCT ID NCT07161843

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the investigational drug QRX-3 can help hospitalized children and adults with acute tubular necrosis, a type of sudden kidney failure. About 500 participants will receive either QRX-3 or a placebo alongside standard care. The main goal is to see if QRX-3 improves kidney function faster than standard treatment alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RENAL FAILURE (ARF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury acute kidney tubular necrosis kidney cortex necrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Neukidney Inc

    Rosharon, Texas, 77583, United States